在肺癌患者中进行纳米粒子癌症治疗的第二阶段试验开始。 Nanobiotix begins Phase 2 trial for nanoparticle cancer treatment in lung cancer patients.

一家生物技术公司Nanobotix已启动名为CONVERGE的第二阶段临床试验,测试JNJ-1900(NBTXR3),这是第3阶段非小型细胞肺癌的纳米粒子治疗。 Nanobiotix, a biotech firm, has started a Phase 2 clinical trial called CONVERGE, testing JNJ-1900 (NBTXR3), a nanoparticle treatment for stage 3 non-small cell lung cancer. 目前正在结合化疗和免疫疗法来评价该疗法,该疗法由通过放射疗法激活的氢氧化纳米粒子组成。 The therapy, composed of hafnium oxide nanoparticles activated by radiotherapy, is being evaluated in combination with chemoradiation and immunotherapy. 纳米生物科旨在将这种治疗扩大到各种固态肿瘤。 Nanobiotix aims to expand this treatment to various solid tumors.